Medical expert of the article
New publications
Preparations
Mexicor
Last reviewed: 04.07.2025

All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.

Indications Mexicor
It is used for combination treatment:
- acute myocardial infarction (starting from the 1st day);
- ischemic stroke;
- DCE (this also includes disorders of atherosclerotic etiology);
- moderate and mild stages of cognitive impairment of various origins.
Release form
The pharmaceutical substance is released in injection liquid, 2 ml per ampoule. The plate contains 5 ampoules, the box contains 2 such plates.
Pharmacodynamics
Mexicor helps improve the activity of the ischemic myocardium in case of infarction, and at the same time improves the contractile activity of the heart and reduces the symptoms of diastolic and systolic left ventricular dysfunction.
The effect of the drug is based on its antioxidant effect and ability to slow down the activity of free radicals (their intensification is observed in the case of necrosis or myocardial ischemia, especially during reperfusion), and also to reduce the damaging effect of free radicals on cardiomyocytes.
In case of critical weakening of coronary blood flow, the drug helps to maintain the functioning and structure of the walls of cardiomyocytes and stimulates the activity of membrane enzymes – AC, PDE and AChE.
The drug potentiates the activation of aerobic glycolysis that occurs in the acute stage of ischemia, and also helps restore oxidation-reduction processes within mitochondria and potentiates the binding of phosphocreatine and ATP. These mechanisms help ensure the integrity of morphological ligaments and the physiological activity of the myocardium affected by ischemia.
The substance stabilizes metabolic processes inside the myocardium affected by ischemia, reduces the area of necrosis, improves or restores contractility and the electrical effect of the myocardium, and at the same time potentiates coronary circulation in the ischemic area and increases the antianginal effect of nitro-containing drugs. In addition, it improves rheological blood parameters and weakens the consequences of reperfusion syndrome developing under the influence of coronary insufficiency (acute nature).
The drug has neuroprotective properties, stabilizes cerebral blood flow during hyperperfusion and improves cerebral blood supply processes during the reperfusion phase after the development of ischemia.
The medication helps to adapt to the damaging ischemic effects, slows down the post-ischemic weakening of glucose and oxygen utilization through the brain and prevents the progressive accumulation of lactate.
The substance improves and normalizes metabolic processes within the brain, as well as cerebral blood supply, and at the same time helps support the functioning of the brain during ischemia and during the post-ischemic phase.
The drug has selective anxiolytic activity, which does not cause muscle relaxation or sedation; Mexicor relieves feelings of fear, anxiety, worry and mental stress.
The drug has nootropic properties, prevents and reduces problems with the ability to remember and learn, which occur with damage to the cerebral vessels or cognitive disorders of a moderate or mild degree. It also has an antihypoxic effect and increases performance with concentration.
When using the medication in combination treatment of individuals with acute stages of cerebral blood flow disorders, the severity of clinical signs is reduced and the course of the rehabilitation period is improved.
Pharmacokinetics
After intravenous injection of the drug, it penetrates tissues and organs at high speed (over a period of 30-90 minutes), due to which its blood indices in an unchanged state quickly decrease. After the use of therapeutic doses of the drug, the plasma level Cmax is noted after 30-40 minutes and is equal to 2.5-3 mcg/ml; metabolic elements are registered in the blood plasma after 7-9 hours. Intrahepatic metabolic processes develop with the help of glucuronidation.
Excretion occurs with urine (glucuronide conjugated state). Only a small portion of the substance is excreted unchanged.
Dosing and administration
Mexicor is administered over a 2-week period either intramuscularly or intravenously, in combination with standard treatment for myocardial infarction.
During the first 5 days, to achieve maximum therapeutic effect, it is recommended to use the drug intravenously, and then (9-day period) it is used intramuscularly.
The substance is administered intravenously through a drip - by infusion, at a low speed (to prevent the development of side effects), with the addition of 0.1-0.15 l of 0.9% NaCl or 5% glucose liquid (the procedure lasts 0.5-1.5 hours). If necessary, jet injection at a low speed can be used, lasting at least 5 minutes.
The medicine is administered intravenously or intramuscularly, 3 times a day, with 8-hour intervals between procedures.
It is necessary to administer 6-9 mg/kg of the drug per day, and 2-3 mg/kg per injection. No more than 0.8 g of the drug is allowed per day, and a maximum of 0.25 g at a time.
In case of acute cerebrovascular accident (with ischemic stroke), the drug is used in combination with other drugs - in the first 2-4 days it is administered intravenously through a dropper (2-3 times a day, 0.2-0.3 g), and later intramuscularly (0.1 g 3 times a day). The duration of such a cycle is 10-14 days. Later, the drug is used in capsules - 0.1 g 2 times a day for a 14-day cycle, and then 0.1 g 3 times a day for a 7-day course. The duration and frequency of repeated cycles are selected by the doctor, taking into account the course of the disease.
In case of decompensated DCE, the drug is administered via a drip, intravenously - in a dose of 0.1 g 2-3 times a day within a 14-day cycle, and then it is taken in capsules, 2-4 times a day, 0.1 g. The prophylactic course consists of intramuscular injections of 0.1 g of the drug 2 times a day for a 10-14-day period.
During the treatment of cognitive impairments of mild or moderate stage, Mexicor is used intramuscularly, in a dose of 0.1-0.3 g per day, for a 2-week period; then, if necessary, capsules are taken - 0.1 g of the drug 2-4 times per day. The duration and mode of use of the drug is selected by the doctor, taking into account the course of the pathology.
Use Mexicor during pregnancy
Mexicor should not be used during pregnancy or breastfeeding.
Side effects Mexicor
After intravenous injection, especially jet injection, a metallic taste or dryness of the oral mucosa, an unpleasant odor and a feeling of heat throughout the body may occur. It is also possible to feel discomfort in the sternum, a sore throat, as well as palpitations, dyspnea, a short-term increase or decrease in blood pressure, tremor, tachycardia with headaches, distal hyperhidrosis and facial hyperemia. Usually, such symptoms occur due to too high a rate of drug administration and are short-lived.
With prolonged use of the medication, the following side effects may develop:
- lesions affecting the gastrointestinal tract: diarrhea, bloating, nausea and dyspeptic disorders;
- disorders associated with the functioning of the central nervous system: sleep problems (difficulty falling asleep or severe sleepiness), feelings of anxiety or weakness, dizziness, coordination disorder, emotional reactivity and peripheral edema.
In case of personal intolerance to the drug, signs of allergy may be observed, including itching, rash, bronchial spasm and Quincke's edema.
[ 22 ]
Overdose
Intoxication can lead to insomnia, and sometimes the opposite – a feeling of drowsiness. Intravenous injections can provoke a weak and short-term increase in blood pressure.
When signs of poisoning appear, relief medications are usually used. The described sleep disorders pass on their own within 24 hours. In extremely severe situations, you should take a sleeping pill and anxiolytic (10 mg oxazepam with nitrazepam and 5 mg diazepam).
If blood pressure readings increase significantly, antihypertensive medications are used, monitoring these readings, or the treatment is supplemented with nitro-containing substances.
Interactions with other drugs
The drug potentiates the effect of anxiolytics from the benzodiazepine group, antiparkinsonian elements (levodopa) and anticonvulsants (carbamazepine). Mexicor also enhances the effect of antihypertensive drugs and nitro-containing components.
Reduces the toxic properties of ethyl alcohol.
Application for children
The medication is not prescribed in pediatrics (under 18 years of age), because there is no data on the possibility of its safe and effective use in this age category.
Analogues
Analogues of the drug are the medications Nuclex, Neocardil, Thiotriazolin with T-Triomax, as well as Metapril with Tivortin Aspartate.
Attention!
To simplify the perception of information, this instruction for use of the drug "Mexicor" translated and presented in a special form on the basis of the official instructions for medical use of the drug. Before use read the annotation that came directly to medicines.
Description provided for informational purposes and is not a guide to self-healing. The need for this drug, the purpose of the treatment regimen, methods and dose of the drug is determined solely by the attending physician. Self-medication is dangerous for your health.